Computer-aided detection does not improve neoplasm detection with colonoscopy
Bookmark1. The GI-Genius neural network system did not improve the rate of detecting advanced...
Read More
Oncology
Younger onset of non-alcoholic fatty liver disease associated with greater cancer risk
Bookmark1. In this case-control study, younger age of onset of non-alcoholic fatty liver disease...
Read More
Prophylactic Radiation Therapy for High-Risk Asymptomatic Bone Metastases
Bookmark1. The hazard ratio of skeletal-related events in patients treated with radiation compared...
Read More
Omission of axilla surgery is non-inferior to sentinel lymph node biopsy in female patients with small breast cancers and clinically negative axillary lymph nodes
Bookmark1. 5-year distant disease-free survival was comparable between both groups. 2. 5-year...
Read More
Tumor Treating Fields vs Standard Therapy in Treatment-Resistant Metastatic NSCLC
Bookmark1. The median OS was 13.2 months with TTFields arm vs 9.9 months with standard arm, with...
Read More
Cetuximab maintenance therapy may be effective for RAS Wild-type metastatic colorectal cancer
Bookmark1. This phase 2 randomized clinical trial found that patients with metastatic colorectal...
Read More
Adjuvant nivolumab may be promising for treatment of completely resected Merkel cell carcinoma
Bookmark1. Disease-free survival at 24 months was 84% in the nivolumab group compared to 73% in...
Read More
Atezolizumab is a potentially effective treatment option for patients with alveolar soft part sarcoma
Bookmark1. 37% of study patients had an objective response to treatment with atezolizumab. 2....
Read More
Patritumab Deruxtecan in EGFR-mutated NSCLC post EGFR TKI and Chemotherapy
Bookmark1. The objective response rate was 29.8% (1% complete response, 66% partial response) with...
Read More
Nivolumab/Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma
Bookmark1. Pooled overall survival and progression-free survival HR were found to be 0.95 and 0.88...
Read More
Vitamin D3 supplementation may improve relapse-free survival for certain digestive tract cancers
Bookmark1. This post-hoc analysis of the AMATERASU randomized clinical trial found that, for...
Read More
Survivors of childhood cancer are less active than their peers
Bookmark1. In a cross-sectional study, adolescent survivors of childhood cancers were more...
Read More
Lisocabtagene maraleucel may induce remission in relapsed chronic lymphocytic leukemia (CLL)
Bookmark1. Complete response or remission was reported in 18% of patients who received a single...
Read More
Cancer mortality after low dose exposure to ionising radiation in workers
Bookmark1. The risk of mortality from solid cancer, lagged by 10 years, is estimated to be...
Read More
Endocrine therapy and breast-conserving surgical management without follow-up radiotherapy is safe in low-risk, luminal A subtype breast cancer
Bookmark1. 5-year recurrence incidence was 2.5% at follow-up. 2. Overall survival at 5 years...
Read More
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Bookmark1. Median progression-free survival was shown to be 27.7 months in the vorasidenib group...
Read More
Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE)
Bookmark1. This phase 2, single-arm, multicenter trial found that in HER2-positive breast cancer...
Read More
Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer
Bookmark1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in...
Read More
Perioperative Nivolumab and Chemotherapy in Stage III NSCLC
Bookmark1. The pathological complete response rate for the experimental group was improved...
Read More
The addition of neoadjuvant and adjuvant pembrolizumab to standard chemotherapy and surgery may improve outcomes in patients with early-stage non-small cell lung cancer
Bookmark1. At 24 months, more participants in the pembrolizumab group were alive without an event,...
Read More